Single‐center outbreak of <i>Pneumocystis jirovecii</i> pneumonia in heart transplant recipients

Veronese, Giacomo; Ammirati, Enrico; Moioli, Maria Cristina; Baldan, Rossella; Orcese, Carlo Andrea; Rezende, Gisele de; Veronese, Silvio; Masciocco, G.; Perna, Enrico; Travi, Giovanna; Puoti, Massimo; Cipriani, Manlio; Tiberi, Simon; Cirillo, Daniela María; Frigerio, Maria

doi:10.1111/tid.12880

Cited by 18 publications

(8 citation statements)

References 33 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy to disclose a cluster of PJP infections have occurred within our transplant center, which adds to the available evidence of inter-human PJP transmission that may occur within transplant centers. [8][9][10] It is important to consider the inherent risk of infection transmission, such as PJP, with repeated exposure to healthcare facilities that are required for BELA infusions.…”

Section: Discussionmentioning

confidence: 99%

Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients

et al. 2022

View full text Add to dashboard Cite

Introduction: Belatacept has demonstrated effectiveness for preventing rejection in kidney transplant and has a favorable side effect profile. Studies assessing long-term infectious complications with belatacept compared to tacrolimus are limited. Project Aims: The purpose of this program evaluation was to determine the proportion of patients who developed an infection when converted to belatacept compared to those on tacrolimus. Design: In this retrospective evaluation, kidney transplant recipients receiving belatacept were matched 1:1 to those receiving tacrolimus, based on transplant date, age, induction immunosuppression, and cytomegalovirus risk. Data collection was initiated in tacrolimus patients on the date of belatacept conversion in the belatacept-matched patients. Data were extracted until study conclusion, death, or discontinuation of belatacept. Patients were stratified into 3 groups based on time of conversion posttransplant, which included early, late, and very late conversion. The primary outcome was the proportion of patients with an infection in belatacept compared to tacrolimus. Outcome data were calculated using chi-square, Fisher's exact test, student's t-test or Mann-Whitney U test where appropriate. Results: A total of 328 matched patients were included in the analysis. More patients on belatacept developed an infection compared to tacrolimus (42.7% vs 29.9%, P = 0.02), which was primarily driven by pneumonia (6.1% vs 0.5%; P = 0.01). Higher incidences of infections were identified in those converted within 6 months from transplant. Conclusions: Belatacept was associated with a higher proportion of patients with infections compared to tacrolimus, particularly in those converted within 6 months from time of transplant.

show abstract

Section: Discussionmentioning

confidence: 99%

Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous clusters were mainly seen in renal transplant recipients 25,26 . However, other SOT patients are also at risk 27 . Patient‐to‐patient transmission of P. jirovecii among recipients of different allografts may cause propagated outbreaks.…”

Section: Discussionmentioning

confidence: 99%

Long‐lasting cluster of nosocomial pneumonia with a single Pneumocystis jirovecii genotype involving different organ allograft recipients

Hosseini-Moghaddam

Dufresne

Gutierrez

et al. 2020

Clinical Transplantation

View full text Add to dashboard Cite

Pneumocystis pneumonia (PCP) outbreaks may occur in solid organ transplant (SOT) patients. Transmissibility of Pneumocystis jirovecii among SOT and non-SOT patients has not been investigated. Ten SOT (ie, 4 heart, 4 kidney, 2 liver allograft recipients) and 11 non-SOT (ie, 7 HIV-infected, 3 hematologic malignancies, and 1 stem cell transplant) patients with PCP were admitted to London Health Sciences Center (LHSC) from October 2014 to August 2016. We investigated the course of illness and outcome of PCP in SOT and non-SOT patients. Post-transplant PCP was frequently an acute-onset disease (90% vs. 18.2%, p = .01) requiring ICU admission (70% vs. 20%, p = .03) and hemodialysis (60% vs. 0, p = .003). Mortality was more frequent in SOT patients (40% vs. 18.1%, p = .36). Multilocus sequence typing (MLST) demonstrated circulation of a single genotype of P. jirovecii among SOT patients. However, 8 different genotypes were detected from non-SOT patients. Reinstitution of prophylaxis successfully controlled post-transplant cluster until end of observation period in October 2019. No transmission was detected from non-SOT patients to SOT recipients. Detection of a single P. jirovecii genotype from all SOT recipients highlights the likelihood of nosocomial transmission. No source control method is recommended by current guidelines. Improvement of preventive strategies is required.

show abstract

“…In HIVnegative PJP, lung involvement is often more severe, with lower arterial-oxygen tension and more frequent respiratory failure. 121,122 The typical signs and symptoms are outlined in ►Table 2. 123,124 The evolution of clinical infection is amplified by the presence of preexisting lung disease (e.g., cytoxan lung, pulmonary fibrosis, and COPD) or other infections (e.g., CMV, Legionella, and mycobacteria).…”

Section: Clinical Presentationmentioning

confidence: 99%

Pneumocystis jiroveci

Fishman

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Pneumocystis jiroveci remains an important fungal pathogen in a broad range of immunocompromised hosts. The natural reservoir of infection remains unknown. Pneumocystis jiroveci Pneumonia (PJP) develops via airborne transmission or reactivation of inadequately treated infection. Nosocomial clusters of infection have been described among immunocompromised hosts. Subclinical infection or colonization may occur. Pneumocystis pneumonia occurs most often within 6 months of organ transplantation and with intensified or prolonged immunosuppression, notably with corticosteroids. Infection is also common during neutropenia and low-lymphocyte counts, with hypogammaglobulinemia, and following cytomegalovirus (CMV) infection. The clinical presentation generally includes fever, dyspnea with hypoxemia, and nonproductive cough. Chest radiographic patterns are best visualized by computed tomography (CT) scan with diffuse interstitial processes. Laboratory examination reveals hypoxemia, elevated serum lactic dehydrogenase levels, and elevated serum (1→3) β-D-glucan assays. Specific diagnosis is achieved using respiratory specimens with direct immunofluorescent staining; invasive procedures may be required and are important to avoid unnecessary therapies. Quantitative nucleic acid amplification is a useful adjunct to diagnosis but may be overly sensitive. Trimethoprim-sulfamethoxazole (TMP-SMX) remains the drug of choice for therapy; drug allergy should be documented before resorting to alternative therapies. Adjunctive corticosteroids may be useful early in the clinical course; aggressive reductions in immunosuppression may provoke immune reconstitution syndromes. Pneumocystis pneumonia (PJP) prophylaxis is recommended and effective for immunocompromised individuals in the most commonly affected risk groups.

show abstract

Single‐center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients

Cited by 18 publications

References 33 publications

Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients

Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients

Long‐lasting cluster of nosocomial pneumonia with a single Pneumocystis jirovecii genotype involving different organ allograft recipients

Pneumocystis jiroveci

Contact Info

Product

Resources

About